Cerebrolysin vs PE-22-28.

Cerebrolysin is a peptide preparation produced by the enzymatic breakdown of purified porcine (pig) brain proteins, yielding a mixture of low-molecular-weight peptides and free amino acids. It is manufactured by EVER Neuro Pharma and given by injection or intravenous infusion rather than orally. Marketed as a neurotrophic and neuroprotective agent, it has been studied across acute ischaemic stroke, vascular dementia, Alzheimer's disease and traumatic brain injury. It is one of the most extensively trialed brain-peptide preparations, yet its clinical benefit remains genuinely contested.

PE-22-28 is a synthetic seven-residue peptide corresponding to residues 22 to 28 of spadin, itself a fragment derived from the sortilin propeptide (also called neurotensin receptor-3). It was developed as a shortened, more stable analog of spadin intended to block the TREK-1 potassium channel. It has been studied as a fast-acting antidepressant candidate in rodent models. It is a preclinical research compound with no human data.

Because Cerebrolysin is a complex biological mixture rather than a single molecule, its mechanism is described as pleiotropic. The peptide fraction is proposed to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity and neurogenesis. Preclinical work also suggests reduced excitotoxicity, anti-apoptotic signaling and effects on amyloid processing. The precise active components and their targets in humans are not fully defined.

PE-22-28 acts by inhibiting the TREK-1 two-pore-domain potassium channel, which is implicated in mood regulation and in resistance to conventional antidepressants. By blocking TREK-1, it is proposed to increase serotonergic neurotransmission and promote hippocampal neurogenesis. Reported potency is high, with a sub-nanomolar IC50 and improved metabolic stability compared with spadin. These effects are characterized in cell and animal systems.

Cerebrolysin has been evaluated in numerous randomized controlled trials, and two Cochrane systematic reviews summarize the best available evidence. The 2023 Cochrane review of acute ischaemic stroke concluded that Cerebrolysin probably has little or no beneficial effect on death or clinical outcome, and it flagged a possible increase in non-fatal serious adverse events, rating certainty of evidence as low to moderate. The 2019 Cochrane review of vascular dementia found possible short-term benefits on cognition and global function but did not recommend routine use, citing small trials, short follow-up and high risk of bias. Several included trials were industry-sponsored, which further tempers confidence. Taken together, the clinical picture is mixed and unsettled rather than clearly positive. The underlying trial set has a distinctive geography: a large share of the randomized evidence originates from centers in Eastern Europe, the CIS, China and parts of Asia, often with the manufacturer as sponsor or provider of study drug, and a substantial portion of the earlier literature was published in languages other than English, which complicates independent appraisal. Trial durations are typically short, on the order of weeks of treatment with follow-up rarely extending to a year, and outcome scales differ between studies, which limits pooling. Later work has continued in narrower settings: a randomized pilot study of speech therapy combined with Cerebrolysin for nonfluent aphasia after acute ischaemic stroke was published in Stroke in 2025, and clinical reviews of neuroprotective and neuroregenerative agents after severe traumatic brain injury continue to describe the evidence as inconclusive. What remains unknown is central rather than peripheral: the active components of the mixture are not identified, so batch-to-batch consistency cannot be verified by potency assay against a defined molecule, and no biomarker predicts response. Even so, Cerebrolysin is the best-studied compound in the animal-tissue peptide category by a wide margin, since preparations such as cortexin, thymalin and vilon have no comparable body of randomized evidence and have never been assessed by Cochrane.

Evidence for PE-22-28 is preclinical only. In the foundational study, shortened spadin analogs including PE-22-28 showed stronger TREK-1 inhibition, longer in-vivo stability and antidepressant-like activity in behavioral tests such as forced swim and novelty-suppressed feeding, along with induction of neurogenesis after a short treatment course (Djillani et al., Frontiers in Pharmacology 2017). A review of TREK-1 blockers situates spadin and its analogs within antidepressant drug discovery (Djillani et al., Pharmacology and Therapeutics 2019). Related work describes the sortilin/NTSR3 origin of spadin and its role in the membrane expression of TREK-1, which supplies the mechanistic rationale for the shortened analogs (Frontiers in Pharmacology, 2018). Separate mouse work using genetic and pharmacological inhibition of TREK-1 reported changes in depression-related behavior and hippocampal neuronal plasticity (CNS Neuroscience and Therapeutics, 2021); that work supports the target as biologically interesting but does not test this peptide. The design of the supporting studies limits the conclusions available. They are rodent experiments run in academic laboratories, largely the group that originated spadin, over short treatment courses. The behavioral readouts are screening assays rather than models of depression: forced swim, tail suspension and novelty-suppressed feeding are sensitive to known antidepressants, which makes them useful filters, but a long list of compounds that performed well in them has failed in human trials. The reports are not blinded multi-centre studies, are not pre-registered, and have not been replicated head to head by an independent group. No completed or registered human clinical trial exists for PE-22-28. There is consequently no Phase 1 safety or tolerability dataset, no human pharmacokinetic profile, no measured central nervous system exposure in people, and no published toxicology package. This is a weaker position than that of compounds it is informally compared with: approved rapid-acting antidepressants such as esketamine were established through randomized, placebo-controlled trials with standard depression rating scales before approval, and even TREK-1 or novel-mechanism candidates that ultimately failed generally reached Phase 1 and produced human exposure and tolerability data. Antidepressant-like signals in rodents do not establish human efficacy or safety.

In trials Cerebrolysin was generally reported as well tolerated, with reactions such as dizziness, headache, agitation, sweating and injection-site effects. Cochrane reviewers noted a possible signal of increased non-fatal serious adverse events in the stroke setting, though this finding was uncertain, and that uncertainty is itself a finding: the trials were not individually powered for safety, adverse-event definitions varied between studies, and reporting completeness differed, so the signal can be neither confirmed nor dismissed from the existing data. As a porcine-derived biological given parenterally, allergic and hypersensitivity reactions are a theoretical concern, and product information in the countries where it is registered describes contraindications including known hypersensitivity, status epilepticus and severe renal impairment. Rapid infusion has been associated with transient reactions such as flushing, dizziness and palpitations. Because the preparation is a complex mixture rather than a single characterized molecule, immunogenicity and lot-to-lot variability are harder to evaluate than for a defined peptide drug. Material obtained outside licensed pharmacy channels adds contamination and counterfeit risk on top of the pharmacological questions, since parenteral products require verified sterility and endotoxin limits. Adequate monitoring in a trial setting includes supervised administration, observation for infusion reactions, renal function assessment, seizure history review and systematic adverse-event capture. It is a clinical product, not a dietary supplement, and any use is a medical decision.

No human safety data exist for PE-22-28; all information comes from short-term rodent studies. There is no published Phase 1 tolerability study, no human pharmacokinetic or elimination data, no immunogenicity assessment, and no repeat-dose or reproductive toxicology package in the public literature. Because TREK-1 is expressed in tissues outside the brain, including cardiovascular, smooth muscle and immune-related tissues, systemic and off-target effects are theoretically possible; the channel also contributes to cellular responses to mechanical and thermal stimuli, so blocking it chronically could have consequences that short rodent behavioral experiments were never designed to detect. Effects on mood-related circuitry are themselves a caution: psychoactive compounds acting on serotonergic signaling and neurogenesis can produce agitation, sleep disruption or worsening mood, and no monitored human exposure exists to characterize any of this. Purity, identity and long-term toxicology of material sold as a research chemical are not controlled. Such products are made outside pharmaceutical good manufacturing practice, carry no verified certificate of analysis for peptide content, impurity profile or endotoxin, and are labeled for laboratory use only. Buyers cannot confirm what the vial holds or whether a reconstituted solution is sterile. The lack of reported adverse events reflects the lack of supervised human use rather than a safety record. With no clinical trials, no pharmacovigilance reporting and no registry, harms occurring in unsupervised use would not be captured. It is not a medicine and is not intended for human use.

Cerebrolysin is not approved by the US FDA and is not marketed in the United States. It is registered and used clinically in a number of countries across Europe, Asia, the CIS and Latin America. This entry is educational only and contains no dosing guidance.

PE-22-28 is not approved by the FDA or any other regulator and has no approved medical use. It exists only as a preclinical research compound. This summary is educational and includes no dosing guidance.